Funcionalidad a los 6 meses en pacientes con diagnóstico reciente de esquizofrenia en tratamiento con Palmitato de Paliperidona trimestral (PP3M) en un estudio de práctica clínica real (Estudio TIME)

Autor: Paz García Portilla, Felisa Gómez, Adolfo Benito, Paola López, Marta García Dorado

Publikováno v: Psicosomática y Psiquiatría, Iss 16 (2021)

Externí odkaz: https://doaj.org/article/bf5f076876a3443c90d82d85e986d7d8

Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain

Autor: Luis, Gutiérrez-Rojas, Sergio, Sánchez-Alonso, Marta, García Dorado, Paola M, López Rengel

Publikováno v: CNS drugs. 36(5)

Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence may increase the risk of relapse, leading to increased hospitalizations and emergency room (ER) visits. Long-acting injectables (LAIs) such as paliper

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::304a0640630122677eaddf3f14f9a6e4
https://pubmed.ncbi.nlm.nih.gov/35460508

Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders

Autor: Teresa Hernando, Eduard Parellada, Miquel Bioque, Berta Herrera, Robin Emsley, Marta García-Dorado

Publikováno v: International Clinical Psychopharmacology. 33:15-33

The aim of this study was to perform a systematic review of the effects of 1-month paliperidone palmitate (PP1M) for the treatment of schizophrenia and related psychotic disorders in terms of outcomes reported in real-world evidence studies. A system

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7663912b873b3e4ca94d88cb74231cc9
https://doi.org/10.1097/yic.0000000000000195

Professionals’ perception on the management of patients with dual disorders

Autor: Carlos Pino, Carlos Roncero, Elena Velasco, Antonio Terán, Marta García-Dorado, Miguel Casas, Nestor Szerman, José María Vázquez

Publikováno v: Patient preference and adherence
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Patient Preference and Adherence
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Europe PubMed Central

Altres ajuts: The editorial support of this article, as well as the survey on which it was based, were financed by Janssen. Carlos Roncero has received fees to give talks for Janssen-Cilag S.A., Bristol-Myers Squibb, Ferrer-Brainpharma, Pfizer, Recki

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb198173cae9d980582c7aa57e3b7de3
http://europepmc.org/articles/PMC5034926

Adherence predicts symptomatic and psychosocial remission in schizophrenia: Naturalistic study of patient integration in the community

Autor: Miguel Bernardo, Berta Herrera, Marta García Dorado, F. Cañas

Publikováno v: Revista de psiquiatria y salud mental. 10(3)

Psychosocial functioning in patients with schizophrenia attended in daily practice is an understudied aspect. The aim of this study was to assess the relationship between symptomatic and psychosocial remission and adherence to treatment in schizophre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::214fca3062406f8e538667d5136e5bf3
https://pubmed.ncbi.nlm.nih.gov/27291833